Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI) of ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

Results from a separate trial that were released in 2022 showed patients taking a high dose of Lilly's (LLY.N), opens new tab Zepbound saw more than 20% weight loss. "The results give us greater ...